A Multi-Center Randomized Double Blind Placebo-Controlled Phase III trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Theraapy following Allogeneic Transplant for patients with FLT3-ITD AML
|Effective start/end date||5/1/17 → 7/31/24|
- NATIONAL MARROW DONOR PROGRAM
- ASTELLAS PHARMA US, INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.